COVID ‐19‐related mortality in a real‐world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK 's Haematological Malignancy Research Network
- 11 November 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 208 (2) , 486-497
Abstract
Summary: When the World Health Organization (WHO) declared the global COVID‐19 pandemic, it was recognised that patients with haematological cancers would be more susceptible to severe disease. Set within a UK population of ~4 million ( https://hmrn.org/ ), all patients diagnosed with haematological neoplasms 2005–2019 who were alive on 1 January 2020 were followed up until March 2023. For comparative purposes, a similar age‐ and sex‐matched general population cohort was also constructed. COVID‐19 deaths were classified using ICD‐10 codes and a multiple cause of death analysis was undertaken using a competing risk approach. Deaths of 486/18 883 haematology patients were attributed to COVID‐19, yielding a cumulative incidence of 2.59% (95% confidence interval [CI]: 2.37–2.82) that was significantly higher than that of the general population (1.65; 95% CI: 1.58–1.72). In both cohorts, risks were higher in men, older people and those with co‐morbidities. Within the patient cohort, excess mortality was largely concentrated in those suffering from more indolent conditions. Patients with the premalignancy MBL suffered from the highest excess mortality in the early phase of the pandemic when, unlike patients with malignancies, they were not advised to shield. Effects of shielding were evident and a clear vaccination benefit was demonstrated, with the exception of CLL and MCL; findings that warrant consideration in relation to other viruses.Keywords
Funding Information
- Cancer Research UK (29685)
- Blood Cancer UK
- National Institute for Health and Care Research (NIHR203331)
This publication has 36 references indexed in Scilit:
- Changes in mortality associated with different hematologic malignancies during the pandemic in the United StatesInternational Journal of Cancer, 2024
- Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registryHematological Oncology, 2023
- Immune cell kinetics and antibody response in COVID‐19 patients with low‐count monoclonal B‐cell lymphocytosisAmerican Journal of Hematology, 2023
- The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLLAmerican Journal of Hematology, 2023
- Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysisClinical and Experimental Medicine, 2023
- Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysisHematological Oncology, 2022
- Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19JAMA Network Open, 2022
- COVID-19 in Children with CancerCurrent Oncology Reports, 2022
- Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosisAmerican Journal of Hematology, 2021
- Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL reportHematological Oncology, 2021